Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will…
